Loading
A phase 1/2 trial of Doxorubicin in brain and spinal cord tumours, run by InSightec, active and no longer recruiting.
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG is a phase 1/2 interventional study registered as NCT05615623 by InSightec, with 10 participants enrolled, started 2023-01-04 and due to reach its primary completion in 2026-06. Interventions recorded: Exablate and Doxorubicin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Insightec, Diffuse midline glioma, H3 K27-altered (including DIPG), Brain and spinal cord tumours (all types), Doxorubicin and the tag pipeline.
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), Glioma & glioblastoma and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/